SEC Company Response from Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Sep 21, 2016
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Sept. 21, 2016 · CIK: 0001604191 · Accession: 0001415889-16-007176
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-212511
Letter
azrxcorrespco_sept212016.htm
AZURRX BIOPHARMA, INC.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
Brooklyn, New York 11226
August 21, 2016
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re:
AzurRx BioPharma, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
Reference is made to the Company’s letter, filed as correspondence via EDGAR on August 21, 2016, in which the Company requested acceleration of the effective date of the above-referenced Registration Statement to August 21, 2016, at 5:00 p.m., or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. We hereby withdraw such request for acceleration of the effective date.
Very truly yours,
AZURRX BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
azrxcorrespco_sept212016.htm
AZURRX BIOPHARMA, INC.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
Brooklyn, New York 11226
August 21, 2016
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re:
AzurRx BioPharma, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
Reference is made to the Company’s letter, filed as correspondence via EDGAR on August 21, 2016, in which the Company requested acceleration of the effective date of the above-referenced Registration Statement to August 21, 2016, at 5:00 p.m., or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. We hereby withdraw such request for acceleration of the effective date.
Very truly yours,
AZURRX BIOPHARMA, INC.
By: /s/ Johan M. (Thijs) Spoor
Name: Johan M. (Thijs) Spoor
Title: President and Chief Executive Officer